NEOGEN CORP
NEOGNasdaqHealthcare · In Vitro & In Vivo Diagnostic Substances · MI · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $894.7M | $924.2M | $822.4M | $527.2M | $468.5M | $418.2M |
| Operating income | −$1.06B | $58.7M | $37.5M | $58.6M | $74.2M | $67.5M |
| Net income | −$1.09B | −$9.4M | −$22.9M | $48.3M | $60.9M | $59.5M |
| Total assets | $3.44B | $4.55B | $4.55B | $992.9M | $920.2M | $797.2M |
| Total liabilities | $1.37B | $1.40B | $1.42B | $105.6M | $79.8M | $72.0M |
| Equity | $2.07B | $3.14B | $3.13B | $887.4M | $840.4M | $725.2M |
| EPS (diluted) | $-5.03 | $-0.04 | $-0.12 | $0.45 | $0.57 | $0.56 |
| Shares out. | 217.2M | 216.7M | 216.3M | 107.8M | 107.5M | 53.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −118.6%
- Net margin
- −122.1%
- Return on equity
- −52.7%
- Return on assets
- −31.7%
- Return on capital (ROCE)
- −32.4%
- Liabilities / assets
- 39.9%
- Debt / equity
- 0.66×
- Book value / share
- $9.54
- Revenue growth (YoY)
- −3.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.23distress
- Accruals / assets
- −33.4%clean
- Beneish M-Score
- -4.25normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Jan 10, 2025
- NT 10-Kmissed a reporting deadline ↗Jul 31, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Clarkston Capital Partners, LlcPassive (13G)May 14, 2026
- Vanguard Capital Management LlcPassive (13G)Apr 30, 2026
- Vanguard Portfolio Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Gates Capital Management, Inc.Passive (13G)Feb 17, 2026
- Ing Groep NvPassive (13G)Dec 4, 2025
- William Blair Investment Management, LlcPassive (13G)Jul 30, 2025
- Norges BankPassive (13G)Jul 24, 2025
- Blackrock, Inc.Passive (13G)Apr 24, 2025
- Select Equity Group, L.P.Passive (13G)Feb 14, 2025
- Baillie Gifford & CoPassive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 10.7M | 5.8 | -3.3% |
| Apr 30, 2026 | 11.1M | 4.7 | +10.6% |
| Apr 15, 2026 | 10.0M | 3.0 | -0.4% |
| Mar 31, 2026 | 10.1M | 4.3 | +11.6% |
| Mar 13, 2026 | 9.0M | 3.1 | -8.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureApr 20, 2026
- Results of operationsApr 9, 2026
- Director / officer changeMar 30, 2026
- Results of operationsJan 8, 2026
- Director / officer change · Other material eventOct 30, 2025
- Shareholder voteOct 27, 2025
- Results of operationsOct 9, 2025
- Director / officer change · Other material eventSep 15, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 144May 29, 2026
- SDMay 20, 2026
- 4PRIMARY DOCUMENTMay 19, 2026
- SCHEDULE 13G/AMay 14, 2026
- 4PRIMARY DOCUMENTMay 5, 2026
- 4PRIMARY DOCUMENTMay 4, 2026
- SCHEDULE 13GApr 30, 2026
- SCHEDULE 13GApr 29, 2026
- 8-KApr 20, 2026
- 3PRIMARY DOCUMENTApr 13, 2026
- 10-QApr 9, 2026
- 8-KApr 9, 2026
- 8-KMar 30, 2026
- SCHEDULE 13G/AMar 27, 2026
- SCHEDULE 13G/AFeb 17, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.